Ribupatide (HRS9531)
GIP/GLP-1 · s.c. · Hengrui / Kailera
Summary
- Also known as
- KAI-9531, Hengrui / Kailera
- Mechanism
- GIP/GLP-1
- Route
- s.c.
- Company
- Hengrui / Kailera
- Highest development stage
- filed
- Status (as of data cut)
- Phase 3 positive in China (GEMINI-1: −17.7 % TP / −19.2 % at 48 weeks); NDA accepted in China (Sep 2025); global phase 3 KaiNETIC enrolled (Kailera) verify
- Next milestone
- China approval; KaiNETIC topline mid-2028
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 3 positive phase 3 | Positive phase 3 in China (GEMINI-1); NDA accepted Sep 2025 | Hengrui NDA announcement (SSE, Sep 2025) |
| T2D | 3 positive phase 3 | Positive phase 3 versus semaglutide (HbA1c −2.78 vs −2.29 %) | |
| CV outcomes | 2 phase 3 ongoing | Phase 3 ongoing | |
| CKD | 0 no data | ||
| HFpEF | 1 phase 2 / signal | Phase 2 only | |
| MASH | 1 phase 2 / signal | Phase 2 only | |
| Sleep apnoea | 2 phase 3 ongoing | Phase 3 ongoing | |
| Knee OA | 2 phase 3 ongoing | Phase 3 ongoing | |
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HRS9531-201 (NCT05881837) | 1.0 mg | obesity china | 24 | 249 | — | −5.4 % vs −0.1 % Δ −5.3 pp | — | 2.0 vs 2.0 | — | 14.3 vs 8.2 | 6.1 vs 2.0 | — | — | congress |
| HRS9531-201 (NCT05881837) | 3.0 mg | obesity china | 24 | 249 | — | −13.4 % vs −0.1 % Δ −13.3 pp | — | 2.0 vs 2.0 | — | 27.5 vs 8.2 | 19.6 vs 2.0 | — | — | congress |
| HRS9531-201 (NCT05881837) | 4.5 mg | obesity china | 24 | 249 | — | −14.0 % vs −0.1 % Δ −13.9 pp | — | 0.0 vs 2.0 | — | 32.0 vs 8.2 | 20.0 vs 2.0 | — | — | congress |
| HRS9531-201 (NCT05881837) | 6.0 mg | obesity china | 24 | 249 | — | −16.8 % vs −0.1 % Δ −16.7 pp | — | 0.0 vs 2.0 | — | 32.7 vs 8.2 | 28.6 vs 2.0 | — | — | congress |
| HRS9531-203 (NCT06054698) | 8 mg | obesity china | 36 | — | −23.6 % | −22.8 % | — | — | — | — | — | — | — | press release |
| HRS9531-T-201 oral ribupatide (NCT06841445) | 10 mg oral QD | obesity china | 26 | 166 | −6.9 % vs −2.3 % Δ −4.6 pp | −6.7 % vs −2.1 % Δ −4.6 pp | — | 0.0 vs 0.0 | — | 11.9 vs 7.5 | 2.4 vs 0.0 | 2.4 vs 2.5 | −6.1 vs −3.9 | press release |
| HRS9531-T-201 oral ribupatide (NCT06841445) | 25 mg oral QD | obesity china | 26 | 166 | −12.1 % vs −2.3 % Δ −9.8 pp | −11.9 % vs −2.1 % Δ −9.8 pp | — | 0.0 vs 0.0 | — | 22.7 vs 7.5 | 11.4 vs 0.0 | 4.5 vs 2.5 | −6.4 vs −3.9 | press release |
| HRS9531-T-201 oral ribupatide (NCT06841445) | 50 mg oral QD | obesity china | 26 | 166 | −12.1 % vs −2.3 % Δ −9.8 pp | −11.4 % vs −2.1 % Δ −9.3 pp | — | 2.5 vs 0.0 | — | 20.0 vs 7.5 | 7.5 vs 0.0 | 0.0 vs 2.5 | −5.1 vs −3.9 | press release |
| Ribupatide in obesity + PMOS (NCT06595797) | 1 mg | obesity china | 32 | 158 | — | −10.0 % vs −2.6 % Δ −7.4 pp | — | 0.0 vs 0.0 | — | — | — | 0.0 vs 0.0 | — | congress |
| Ribupatide phase 2 (obesity + PMOS) | ribupatide 4 mg | obesity china | 32 | 158 | — | −20.2 % vs −2.6 % Δ −17.6 pp | — | 0.0 vs 0.0 | — | — | — | 0.0 vs 0.0 | — | verified |
| Ribupatide phase 2 (obesity + PMOS) | ribupatide 2 mg | obesity china | 32 | 158 | — | −15.1 % vs −2.6 % Δ −12.5 pp | — | 0.0 vs 0.0 | — | — | — | 0.0 vs 0.0 | — | verified |
| HRS9531-301 (GEMINI-1, NCT06396429) | 2 mg | obesity china | 48 | 567 | −11.2 % vs −1.4 % Δ −9.8 pp | −10.7 % vs −1.4 % Δ −9.3 pp | — | 0.7 vs 0.0 | — | 16.2 vs 4.9 | 14.1 vs 2.1 | 1.4 vs 5.6 | — | press release |
| HRS9531-301 (GEMINI-1, NCT06396429) | 4 mg | obesity china | 48 | 567 | −17.4 % vs −1.4 % Δ −16.0 pp | −16.4 % vs −1.4 % Δ −15.0 pp | — | 0.7 vs 0.0 | — | 17.0 vs 4.9 | 19.1 vs 2.1 | 5.0 vs 5.6 | — | press release |
| HRS9531-301 (GEMINI-1, NCT06396429) | 6 mg | obesity china | 48 | 567 | −19.2 % vs −1.4 % Δ −17.8 pp | −17.7 % vs −1.4 % Δ −16.3 pp | — | 1.4 vs 0.0 | — | 27.0 vs 4.9 | 24.1 vs 2.1 | 4.3 vs 5.6 | — | press release |
| Ribupatide T2D phase 3 after metformin +/- SGLT2i (NCT06649344) | 4 mg vs semaglutide 1 mg: HbA1c -2.29 | t2d china | 36 | — | — | — | −2.8 | — | — | — | — | — | — | press release |
| Ribupatide T2D phase 3 after metformin +/- SGLT2i (NCT06649344) | 2 mg vs semaglutide 1 mg: HbA1c -2.29 | t2d china | 36 | — | — | — | −2.3 | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- ribupatide 4 mg: Treatment-policy estimand; duration to confirm from the abstract; duration 32 weeks per the abstract (both models agree) Per-arm N for the zero counts inferred from the reported percentages (≈39–40).
- ribupatide 2 mg: duration 32 weeks per the abstract (both models agree) Per-arm N for the zero counts inferred from the reported percentages (≈39–40).
Verbatim quotes from the source (68)
- ribupatide 4 mg · weight_tp · Results
the least-squares (LS) mean percentage weight change was -10.0%, -15.1% and -20.2% for the ribupatide 1 mg, 2 mg and 4 mg, respectively, versus -2.6% with placebo
- ribupatide 4 mg · ae_dc · Results
No serious AEs, adverse events of special interest (AESI) or AEs leading to treatment discontinuation occurred.
- ribupatide 4 mg · sae · Results
No serious AEs, adverse events of special interest (AESI) or AEs leading to treatment discontinuation occurred.
- ribupatide 2 mg · weight_tp · Results
the least-squares (LS) mean percentage weight change was -10.0%, -15.1% and -20.2% for the ribupatide 1 mg, 2 mg and 4 mg, respectively, versus -2.6% with placebo
- ribupatide 2 mg · ae_dc · Results
No serious AEs, adverse events of special interest (AESI) or AEs leading to treatment discontinuation occurred.
- ribupatide 2 mg · sae · Results
No serious AEs, adverse events of special interest (AESI) or AEs leading to treatment discontinuation occurred.
- 2 mg · weight_tp · press release
Based on the treatment policy estimand^II, participants taking HRS9531 achieved a mean weight loss of 10.7% (2 mg), 16.4% (4 mg) and 17.7% (6 mg), compared to placebo (1.4%).
- 2 mg · ae_dc · press release
Permanent treatment discontinuation rates due to TEAEs were very low with 0.7% (1 participant, 2 mg), 0.7% (1 participant, 4 mg), 1.4% (2 participants, 6 mg) and 0% (placebo).
- 2 mg · nausea · abstract
Nausea 7 (4.9) 23 (16.2) 24 (17.0) 38 (27.0)
- 2 mg · vomiting · abstract
Vomiting 3 (2.1) 20 (14.1) 27 (19.1) 34 (24.1)
- 2 mg · sae · abstract
SAEs 8 (5.6) 2 (1.4) 7 (5.0) 6 (4.3)
- 2 mg · weight_eff · press release
Based on the hypothetical strategy estimand^I, participants taking HRS9531 achieved a mean weight loss of 11.2% (2 mg), 17.4% (4 mg) and 19.2% (6 mg), compared to placebo (1.4%).
- 4 mg · weight_tp · press release
Based on the treatment policy estimand^II, participants taking HRS9531 achieved a mean weight loss of 10.7% (2 mg), 16.4% (4 mg) and 17.7% (6 mg), compared to placebo (1.4%).
- 4 mg · ae_dc · press release
Permanent treatment discontinuation rates due to TEAEs were very low with 0.7% (1 participant, 2 mg), 0.7% (1 participant, 4 mg), 1.4% (2 participants, 6 mg) and 0% (placebo).
- 4 mg · nausea · abstract
Nausea 7 (4.9) 23 (16.2) 24 (17.0) 38 (27.0)
- 4 mg · vomiting · abstract
Vomiting 3 (2.1) 20 (14.1) 27 (19.1) 34 (24.1)
- 4 mg · sae · abstract
SAEs 8 (5.6) 2 (1.4) 7 (5.0) 6 (4.3)
- 4 mg · weight_eff · press release
Based on the hypothetical strategy estimand^I, participants taking HRS9531 achieved a mean weight loss of 11.2% (2 mg), 17.4% (4 mg) and 19.2% (6 mg), compared to placebo (1.4%).
- 6 mg · weight_tp · press release
Based on the treatment policy estimand^II, participants taking HRS9531 achieved a mean weight loss of 10.7% (2 mg), 16.4% (4 mg) and 17.7% (6 mg), compared to placebo (1.4%).
- 6 mg · ae_dc · press release
Permanent treatment discontinuation rates due to TEAEs were very low with 0.7% (1 participant, 2 mg), 0.7% (1 participant, 4 mg), 1.4% (2 participants, 6 mg) and 0% (placebo).
- 6 mg · nausea · abstract
Nausea 7 (4.9) 23 (16.2) 24 (17.0) 38 (27.0)
- 6 mg · vomiting · abstract
Vomiting 3 (2.1) 20 (14.1) 27 (19.1) 34 (24.1)
- 6 mg · sae · abstract
SAEs 8 (5.6) 2 (1.4) 7 (5.0) 6 (4.3)
- 6 mg · weight_eff · press release
Based on the hypothetical strategy estimand^I, participants taking HRS9531 achieved a mean weight loss of 11.2% (2 mg), 17.4% (4 mg) and 19.2% (6 mg), compared to placebo (1.4%).
- 8 mg · weight_tp · press release
participants taking the 8 mg dose of HRS9531 achieved a mean weight loss of 22.8% (21.1% placebo-adjusted) at week 36
- 8 mg · weight_eff · press release
mean weight loss with the 8 mg dose of HRS9531 was 23.6% (21.7% placebo-adjusted)
- 1.0 mg · weight_tp · abstract
in body weight was -5.4% (95% CI -7.3% to -3.5%), -13.4% (-15.2% to -
- 1.0 mg · nausea · abstract
Nausea 7 (14.3) 14 (27.5) 16 (32.0) 16 (32.7) 4 (8.2)
- 1.0 mg · vomiting · abstract
Vomiting 3 (6.1) 10 (19.6) 10 (20.0) 14 (28.6) 1 (2.0)
- 1.0 mg · ae_dc · Table 3 (Adverse events), columns 1.0/3.0/4.5/6.0 mg/placebo
1 (2.0) 1 (2.0) 0 0 1 (2.0)
- 3.0 mg · weight_tp · abstract
in body weight was -5.4% (95% CI -7.3% to -3.5%), -13.4% (-15.2% to -
- 3.0 mg · nausea · abstract
Nausea 7 (14.3) 14 (27.5) 16 (32.0) 16 (32.7) 4 (8.2)
- 3.0 mg · vomiting · abstract
Vomiting 3 (6.1) 10 (19.6) 10 (20.0) 14 (28.6) 1 (2.0)
- 3.0 mg · ae_dc · Table 3 (Adverse events), columns 1.0/3.0/4.5/6.0 mg/placebo
1 (2.0) 1 (2.0) 0 0 1 (2.0)
- 4.5 mg · weight_tp · abstract
11.5%), -14.0% (-15.9% to -12.1%), and -16.8% (-18.8% to -14.9%) in the
- 4.5 mg · nausea · abstract
Nausea 7 (14.3) 14 (27.5) 16 (32.0) 16 (32.7) 4 (8.2)
- 4.5 mg · vomiting · abstract
Vomiting 3 (6.1) 10 (19.6) 10 (20.0) 14 (28.6) 1 (2.0)
- 4.5 mg · ae_dc · Table 3 (Adverse events), columns 1.0/3.0/4.5/6.0 mg/placebo
1 (2.0) 1 (2.0) 0 0 1 (2.0)
- 6.0 mg · weight_tp · abstract
11.5%), -14.0% (-15.9% to -12.1%), and -16.8% (-18.8% to -14.9%) in the
- 6.0 mg · nausea · abstract
Nausea 7 (14.3) 14 (27.5) 16 (32.0) 16 (32.7) 4 (8.2)
- 6.0 mg · vomiting · abstract
Vomiting 3 (6.1) 10 (19.6) 10 (20.0) 14 (28.6) 1 (2.0)
- 6.0 mg · ae_dc · Table 3 (Adverse events), columns 1.0/3.0/4.5/6.0 mg/placebo
1 (2.0) 1 (2.0) 0 0 1 (2.0)
- 10 mg oral QD · weight_tp · press release
Based on the treatment policy estimand^II at Week 26, participants taking oral ribupatide achieved a mean weight loss of 6.7% (10 mg), 11.9% (25 mg), and 11.4% (50 mg)
- 10 mg oral QD · nausea · abstract
Nausea 5 (11.9) 10 (22.7) 8 (20.0) 3 (7.5)
- 10 mg oral QD · vomiting · abstract
Vomiting 1 (2.4) 5 (11.4) 3 (7.5) 0
- 10 mg oral QD · sae · abstract
SAEs* 1 (2.4) 2 (4.5) 0 1 (2.5)
- 10 mg oral QD · ae_dc · abstract
TEAEs leading to treatment discontinuation 0 0 1 (2.5)# 0
- 10 mg oral QD · sbp · abstract
SBP, mmHg, LS mean (SE) -6.1 (1.4) -6.4 (1.3) -5.1 (1.4) -3.9 (1.5)
- 10 mg oral QD · weight_eff · press release
Based on the efficacy estimand^I at Week 26, participants taking oral ribupatide achieved a mean weight loss of 6.9% (10 mg), 12.1% (25 mg), and 12.1% (50 mg)
- 25 mg oral QD · weight_tp · press release
Based on the treatment policy estimand^II at Week 26, participants taking oral ribupatide achieved a mean weight loss of 6.7% (10 mg), 11.9% (25 mg), and 11.4% (50 mg)
- 25 mg oral QD · nausea · abstract
Nausea 5 (11.9) 10 (22.7) 8 (20.0) 3 (7.5)
- 25 mg oral QD · vomiting · abstract
Vomiting 1 (2.4) 5 (11.4) 3 (7.5) 0
- 25 mg oral QD · sae · abstract
SAEs* 1 (2.4) 2 (4.5) 0 1 (2.5)
- 25 mg oral QD · ae_dc · abstract
TEAEs leading to treatment discontinuation 0 0 1 (2.5)# 0
- 25 mg oral QD · sbp · abstract
SBP, mmHg, LS mean (SE) -6.1 (1.4) -6.4 (1.3) -5.1 (1.4) -3.9 (1.5)
- 25 mg oral QD · weight_eff · press release
Based on the efficacy estimand^I at Week 26, participants taking oral ribupatide achieved a mean weight loss of 6.9% (10 mg), 12.1% (25 mg), and 12.1% (50 mg)
- 50 mg oral QD · weight_tp · press release
Based on the treatment policy estimand^II at Week 26, participants taking oral ribupatide achieved a mean weight loss of 6.7% (10 mg), 11.9% (25 mg), and 11.4% (50 mg)
- 50 mg oral QD · nausea · abstract
Nausea 5 (11.9) 10 (22.7) 8 (20.0) 3 (7.5)
- 50 mg oral QD · vomiting · abstract
Vomiting 1 (2.4) 5 (11.4) 3 (7.5) 0
- 50 mg oral QD · sae · abstract
SAEs* 1 (2.4) 2 (4.5) 0 1 (2.5)
- 50 mg oral QD · ae_dc · abstract
TEAEs leading to treatment discontinuation 0 0 1 (2.5)# 0
- 50 mg oral QD · sbp · abstract
SBP, mmHg, LS mean (SE) -6.1 (1.4) -6.4 (1.3) -5.1 (1.4) -3.9 (1.5)
- 50 mg oral QD · weight_eff · press release
Based on the efficacy estimand^I at Week 26, participants taking oral ribupatide achieved a mean weight loss of 6.9% (10 mg), 12.1% (25 mg), and 12.1% (50 mg)
- 1 mg · weight_tp · abstract
mean percentage weight change was -10.0%, -15.1% and -20.2% for the ribupatide 1
- 1 mg · ae_dc · abstract, Results (last sentences)
No serious AEs, adverse events of special interest (AESI) or AEs leading to treatment discontinuation occurred.
- 1 mg · sae · abstract, Results (last sentences)
No serious AEs, adverse events of special interest (AESI) or AEs leading to treatment discontinuation occurred.
- 4 mg · hba1c · press release
the mean HbA1c reductions in the ribupatide injection 4 mg and 2 mg groups reached 2.78% and 2.34%, respectively, compared to 2.29% in the semaglutide injection 1 mg group
- 2 mg · hba1c · press release
the mean HbA1c reductions in the ribupatide injection 4 mg and 2 mg groups reached 2.78% and 2.34%, respectively, compared to 2.29% in the semaglutide injection 1 mg group
Registered trials (15)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| NCT07670884 A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects | Obesity | Phase 3 | recruiting | 2026-07 → 2027-10 | 675 | recruiting | NCT07670884 |
| NCT07709910 A Trial of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis | Knee OA | Phase 3 | not yet recruiting | 2026-07 → 2028-11 | 382 | not yet recruiting | NCT07709910 |
| ASCVD A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease | CV outcomes | Phase 3 | recruiting | 2026-05 → 2031-05 | 9262 | recruiting | NCT07551492 |
| KaiNETIC-2 Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes | Obesity | Phase 3 | active not recruiting | 2026-01 → 2028-03 | 1270 | active not recruiting | NCT07284901 |
| KaiNETIC-1 Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes | Obesity | Phase 3 | active not recruiting | 2025-12 → 2028-02 | 2530 | active not recruiting | NCT07284875 |
| KaiNETIC-3 Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes | Obesity | Phase 3 | active not recruiting | 2025-12 → 2028-03 | 1270 | active not recruiting | NCT07284979 |
| NCT07285902 A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity | Obesity | Phase 3 | active not recruiting | 2025-12 → 2027-03 | 572 | active not recruiting | NCT07285902 |
| NCT06994650 A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy | Sleep apnoea | Phase 3 | active not recruiting | 2025-08 → 2026-12 | 144 | active not recruiting | NCT06994650 |
| NCT06974851 A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity | Sleep apnoea | Phase 3 | recruiting | 2025-07 → 2026-12 | 140 | recruiting | NCT06974851 |
| NCT07060456 Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin | T2D | Phase 3 | recruiting | 2025-07 → 2027-02 | 300 | recruiting | NCT07060456 |
| NCT06650007 the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone | T2D | Phase 3 | completed | 2024-11 → 2026-01 | 218 | Completed; results not in the atlas yet | NCT06650007 |
| NCT06649344 A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes | T2D | Phase 3 | completed | 2024-10 → 2026-07 | 884 | Completed; results not in the atlas yet | NCT06649344 |
| NCT06565871 A Study of HRS9531 Injection in Obese Subjects With Obstructive Sleep Apnea | Sleep apnoea | Phase 2 | unknown | 2024-08 → 2025-12 | 108 | unknown | NCT06565871 |
| NCT06391710 HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction | HFpEF | Phase 2 | active not recruiting | 2024-05 → 2026-01 | 203 | active not recruiting | NCT06391710 |
| NCT06396429 To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese | Obesity | Phase 3 | completed | 2024-05 → 2025-07 | 567 | Completed; results not in the atlas yet | NCT06396429 |
Primary sources
- Hongwei Jiang et al. Efficacy and safety of ribupatide (HRS9531) in participants with obesity and polyendocrine metabolic ovarian syndrome (PMOS): a multicentre, randomised, double-blind, Phase 2 trial. Abstract LBA 74. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. [Session: LBA SO 05 Diabetes in pregnancy, childhood and beyond]
- EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. Abstract easd66738.
- Hengrui / Kailera. Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531 (GlobeNewswire text mirrored by santelog.com) [press release]. 2025-11-04. Available from: https://www.santelog.com/actualites-sante-nasdaq/hengrui-pharma-and-kailera-therapeutics-announce-additional-data-phase-3
- EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. Abstract hrs9531_ow2025_slides.
- Hengrui / Kailera. Hengrui Pharma and Kailera Therapeutics Report Positive Topline Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531 (GlobeNewswire via BioSpace) [press release]. 2025-07-15. Available from: https://www.biospace.com/press-releases/hengrui-pharma-and-kailera-therapeutics-report-positive-topline-data-from-phase-3-obesity-trial-in-china-of-dual-glp-1-gip-receptor-agonist-hrs9531
- EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. Abstract hrs9531_201_ada2024.
- EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. Abstract hrs9531t201_ada2026_poster.
- Kailera / Hengrui. Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide (GlobeNewswire via BioSpace) [press release]. 2026-02-10. Available from: https://www.biospace.com/press-releases/kailera-therapeutics-and-hengrui-pharma-report-positive-topline-data-from-phase-2-obesity-trial-of-oral-ribupatide
- Kailera. Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates (8-K Ex. 99.1) [press release]. 2026-08-12. Available from: https://www.sec.gov/Archives/edgar/data/2096997/000119312526346919/ck0002096997-ex99_1.htm
How to cite this page
Cite the primary publication for any single result; every value above links to it.